Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rogler

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Gut|July 20, 2006
Significance of anti-inflammatory effects of PPARgamma agonists?G Rogler
Deutsche Medizinische Wochenschrift (1946)|September 12, 2008
[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases]G Rogler
Deutsche Medizinische Wochenschrift (1946)|September 5, 2013
[Treatment of chronic inflammatory bowel disease based on evidence and according to stage: step up]G Rogler
Alimentary Pharmacology & Therapeutics|March 18, 2015
Editorial: is thalidomide a good option for patients with refractory Crohn's disease?G Rogler
Deutsche Medizinische Wochenschrift (1946)|December 4, 2003
[Scientific concepts in clinical medicine]G Rogler
Alimentary Pharmacology & Therapeutics|February 5, 2016
Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?G Rogler
World Journal of Surgery|April 2, 1998
Cytokines in inflammatory bowel diseaseG Rogler, T Andus
Endoscopy|January 20, 2005
Inflammatory bowel diseaseH Herfarth, G Rogler
Deutsche Medizinische Wochenschrift (1946)|November 4, 2010
[Biologicals in gastroenterology: TNF-blockers]M Scharl, G Rogler
Deutsche Medizinische Wochenschrift (1946)|January 9, 2001
["Evidence-biased medicine"--or: the deceptive certainty of the evidence]G Rogler, J Schölmerich
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Gut|July 20, 2006
Significance of anti-inflammatory effects of PPARgamma agonists?G Rogler
Deutsche Medizinische Wochenschrift (1946)|September 12, 2008
[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases]G Rogler
Deutsche Medizinische Wochenschrift (1946)|September 5, 2013
[Treatment of chronic inflammatory bowel disease based on evidence and according to stage: step up]G Rogler
Alimentary Pharmacology & Therapeutics|March 18, 2015
Editorial: is thalidomide a good option for patients with refractory Crohn's disease?G Rogler
Deutsche Medizinische Wochenschrift (1946)|December 4, 2003
[Scientific concepts in clinical medicine]G Rogler
Alimentary Pharmacology & Therapeutics|February 5, 2016
Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?G Rogler
World Journal of Surgery|April 2, 1998
Cytokines in inflammatory bowel diseaseG Rogler, T Andus
Endoscopy|January 20, 2005
Inflammatory bowel diseaseH Herfarth, G Rogler
Deutsche Medizinische Wochenschrift (1946)|November 4, 2010
[Biologicals in gastroenterology: TNF-blockers]M Scharl, G Rogler
Deutsche Medizinische Wochenschrift (1946)|January 9, 2001
["Evidence-biased medicine"--or: the deceptive certainty of the evidence]G Rogler, J Schölmerich
Pageof 14